Rezolute to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Rezolute (Nasdaq: RZLT), a late-stage rare disease company specializing in hypoglycemia treatment caused by hyperinsulinism, has announced its participation in three major upcoming investor conferences in September 2025.

The company will attend the Cantor Global Healthcare Conference (September 3-5), the H.C. Wainwright Global Investment Conference (September 8-10), and the Morgan Stanley Global Healthcare Conference (September 8-10). Management will engage in Fireside Chats and one-on-one meetings with investors during these events.

REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences:

Event: Cantor Global Healthcare Conference
Date: September 3-5, 2025

Event: H.C. Wainwright 27^th Annual Global Investment Conference
Date: September 8-10, 2025

Event: Morgan Stanley 23^rd Annual Global Healthcare Conference
Date: September 8-10, 2025

Management will be participating in Fireside Chats and one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their Cantor, H.C. Wainwright, and Morgan Stanley representatives.

About Rezolute, Inc.

Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (“HI”). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown meaningful benefit in clinical trials and real-world use for the treatment of congenital HI and tumor HI. For more information, visit www.rezolutebio.com.

Contact:

Rezolute, Inc.
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717

FAQ

When is Rezolute (RZLT) presenting at the Cantor Global Healthcare Conference 2025?

Rezolute will participate in the Cantor Global Healthcare Conference from September 3-5, 2025.

Which investor conferences will Rezolute (RZLT) attend in September 2025?

Rezolute will attend three conferences: the Cantor Global Healthcare Conference (Sept 3-5), H.C. Wainwright Global Investment Conference (Sept 8-10), and Morgan Stanley Global Healthcare Conference (Sept 8-10).

How can investors meet with Rezolute management at these conferences?

Investors interested in meeting with Rezolute management should contact their Cantor, H.C. Wainwright, or Morgan Stanley representatives to schedule one-on-one meetings.

What is Rezolute's (RZLT) main business focus?

Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism.